(NYSEMKT: NRXS) Neuraxis's forecast annual revenue growth rate of 80.03% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 46.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 15.31%.
Neuraxis's revenue in 2026 is $5,316,119.On average, 4 Wall Street analysts forecast NRXS's revenue for 2026 to be $124,937,204, with the lowest NRXS revenue forecast at $114,539,375, and the highest NRXS revenue forecast at $134,493,663. On average, 3 Wall Street analysts forecast NRXS's revenue for 2027 to be $265,144,650, with the lowest NRXS revenue forecast at $254,746,821, and the highest NRXS revenue forecast at $272,943,022.
In 2027, NRXS is forecast to generate $265,144,650 in revenue, with the lowest revenue forecast at $254,746,821 and the highest revenue forecast at $272,943,022.